Legal Representation
Attorney
Roman Fayerberg
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 6, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Jun 5, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 5, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Oct 15, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 15, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 15, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 13, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 13, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 12, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 7, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 6, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 9, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 8, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 8, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 8, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 8, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 8, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 24, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 12, 2020 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 11, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 27, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Platelets that are not bone marrow-derived, platelet variants, megakaryocytes, megakaryocytes variants, and products derived from platelets, megakaryocytes or their variants, and admixtures, namely, extracellular vesicles or exosomes, all the foregoing for medical or clinical use; platelet variants for medical or clinical use; pharmaceutical and drug delivery compositions comprising platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; Pharmaceutical compositions for drug delivery comprising non bone marrow-derived platelets, platelet variants for treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; pharmaceutical compositions comprising platelet variants for transfusion in oncology, trauma and surgery; platelet variants for delivering proteins, antibodies, nucleic acids and other drugs to tumors, sites of vascular injury and inflammation, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders and orthopedics; platelet variants for the treatment of tumors, immune-oncology, hematology, cardiovascular, inflammatory, immune and autoimmune diseases, conditions, or responses, critical care disorders, conditions and injuries, solid organ transplantation, wound healing, neurological disorders, and orthopedics; platelet variants as source for growth factors for medical or clinical use; compositions comprising viral vectors for medical or clinical use
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the word PLATELETBIO to the left of a Pegasus design.
Pseudo Mark
PLATELET BIO
Classification
International Classes
005